Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy

Publisher： John Wiley & Sons Inc

E-ISSN： 1099-1069|33|2|57-66

ISSN： 0278-0232

Source： Hematological Oncology (Electronic), Vol.33, Iss.2, 2015-06, pp. : 57-66

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Utility of DNA Methyltransferase Inhibitors for the Treatment of Myelodysplastic Syndromes

By  

Current Pharmaceutical Design, Vol. 18, Iss. 22, 2012-07 ,pp. : 3190-3197

Bentham Science Publishers

Access to resources Recommend Favorite

Real-time nanoscale proteomic analysis of the novel multi-kinase pathway inhibitor rigosertib to measure the response to treatment of cancer

By Fan Alice C   O'Rourke Jennifer J   Praharaj Dave R   Felsher Dean W  

Expert Opinion on Investigational Drugs, Vol. 22, Iss. 11, 2013-11 ,pp. : 1495-1509

Informa Healthcare

Access to resources Recommend Favorite

Immunosuppressive Therapy for Myelodysplastic Syndromes

By  

Current Pharmaceutical Design, Vol. 18, Iss. 22, 2012-07 ,pp. : 3184-3189

Bentham Science Publishers

Access to resources Recommend Favorite

Six (or More) Drugs in Search of a Mechanism: DNA Methyltransferase and Histone Deacetylase Inhibitors in the Treatment of Myelodysplastic Syndromes

By Gore Steven D.  

Journal of the National Comprehensive Cancer Network (JNCCN), Vol. 4, Iss. 1, 2006-01 ,pp. : 83-90

Cambridge Scholars Publishing in association with GSE Research

Access to resources Recommend Favorite

Dual protease inhibitor therapy in the management of the HIV-1

By Yu K.   Daar E.S.  

Expert Opinion on Pharmacotherapy, Vol. 1, Iss. 7, 2000-12 ,pp. : 1331-1342

Informa Healthcare

Access to resources Recommend Favorite